MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from
financings, net of issuance...
$256,313K
Proceeds from exercise of
stock options and rsus...
$4,077K
Proceeds from maturities
of marketable...
$246,000K
Net cash provided by
financing activities
$257,029K
Net cash provided by
investing activities
$14,039K
Effect of exchange rate
changes on cash, cash...
$1,074K
Canceled cashflow
$3,361K
Canceled cashflow
$231,961K
Net increase
(decrease) increase in...
$148,799K
Canceled cashflow
$123,343K
Withholding taxes paid on
stock-based awards
$3,361K
Stock-based compensation
expense
$27,645K
Prepaid expenses and
other current assets
-$5,960K
Operating lease
right-of-use assets
$1,730K
Accounts payable
$580K
Depreciation expense
$525K
Accounts receivable, net
-$359K
Interest receivable
-$24K
Purchases of investments
$231,823K
Purchases of property and
equipment
$138K
Net cash used in
operating activities
-$123,343K
Canceled cashflow
$36,823K
Net loss
-$144,735K
Accrued expenses
-$6,598K
Accretion of investment
discounts, net
$5,526K
Deposits and other assets
$1,976K
Operating lease
liabilities
-$1,162K
Other non-cash items
$169K
Back
Back
Cash Flow
source: myfinsight.com
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX)